About 11 results found for searched term "H-1-Nal-OH" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M39523 | H-1-Nal-OH | Amino Acid Derivatives |
| H-1-Nal-OH is an alanine derivative. | ||
| M40986 | NGM-313 | FGFR |
| MK-3655 | ||
| NGM-313 is a β-Klotho/FGFR1c-targeted monoclonal antibody for studies related to non-alcoholic steatohepatitis (NASH). | ||
| M21185 | BMS-986318 | Farnesoid X Receptor |
| BMS-986318 is a potent non-bile acid FXR agonist with an EC50 of 53 and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has suitable ADME properties and is effective in a mouse model of hepatic cholestasis and fibrosis with bile duct ligation.BMS-986318 can be used in nonalcoholic steato BMS-986318 can be used in non-alcoholic steatohepatitis (NASH) studies. | ||
| M24739 | Aldafermin | Others |
| NGM282 | ||
| Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH). | ||
| M24907 | Pegbelfermin | FGFR |
| BMS-986036 | ||
| Pegbelfermin (BMS-986036) is a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21). Pegbelfermin can be used for the research of nonalcoholic steatohepatitis (NASH). | ||
| M25227 | Golimumab | TNF Receptor |
| CNTO-148 | ||
| Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research. | ||
| M25245 | Leronlimab | CCR |
| PRO 140 | ||
| Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer. | ||
| M25301 | Eldelumab | CXCR |
| BMS-936557; MDX-1100 | ||
| Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. | ||
| M29847 | BI‑3231 | Hydroxysteroid dehydrogenase |
| BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases. | ||
| M31160 | HEC96719 | Farnesoid X Receptor |
| HEC-96719 | ||
| HEC96719 is a novel, selective, orally active tricyclic FXR agonist that activates FXR and induces expression of the target genes FGF15 and BSEP for nonalcoholic steatohepatitis (NASH) studies. | ||
| M49467 | Carfloglitazar sodium | PPAR |
| Chiglitazar sodium | ||
| Carfloglitazar sodium is a dual agonist of the pan peroxisome proliferator-activated receptor (PPARα/γ) with EC50 values of 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ, respectively.It can be used in studies related to nonalcoholic steatohepatitis (NASH). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
